科美诊断(688468) - 2025 Q3 - 季度财报

Financial Performance - Total revenue for Q3 2025 was ¥96,206,475.83, a decrease of 18.61% compared to the same period last year[3] - Net profit attributable to shareholders was ¥17,221,945.26, down 51.50% year-over-year[3] - The total profit for the year-to-date period decreased by 63.92% to ¥46,155,660.46[3] - Basic earnings per share for Q3 2025 was ¥0.04, a decline of 55.56% compared to the previous year[3] - The company's revenue for the reporting period was CNY 260.82 million, a year-on-year decrease of 24.13%[12] - Net profit attributable to shareholders was CNY 41.56 million, down 62.94% year-on-year[12] - Total operating revenue for the first three quarters of 2025 was CNY 260,821,861.59, a decrease of 24.1% compared to CNY 343,786,670.77 in the same period of 2024[19] - Net profit for the first three quarters of 2025 was CNY 41,562,776.02, a decline of 63.0% compared to CNY 112,150,960.47 in the same period of 2024[20] - Operating profit for the first three quarters of 2025 was CNY 45,983,456.08, down 64.0% from CNY 128,141,009.06 in the previous year[20] Research and Development - R&D investment totaled ¥20,744,668.54, representing 21.56% of total revenue, an increase of 4.92 percentage points[4] - The company continues to invest in R&D, focusing on innovative products and technologies to meet clinical needs[12] - Research and development expenses increased to CNY 56,428,488.49 in 2025, up 15.0% from CNY 48,830,331.80 in 2024[20] Cash Flow and Assets - The net cash flow from operating activities for the year-to-date period was ¥71,178,778.38, down 47.41% year-over-year[3] - Cash and cash equivalents increased to CNY 648.39 million from CNY 400.25 million as of December 31, 2024[15] - Total current assets decreased to CNY 1,030.99 million from CNY 1,067.68 million[15] - The company's cash flow from operating activities for the first three quarters of 2025 showed a significant change, reflecting ongoing adjustments in operational efficiency[22] - Cash inflow from operating activities for the first three quarters of 2025 was $300.41 million, a decrease of 27% compared to $411.58 million in the same period of 2024[23] - Net cash flow from operating activities for the first three quarters of 2025 was $71.18 million, down 47.4% from $135.33 million in 2024[24] - Total assets at the end of the reporting period were ¥1,771,711,225.11, a decrease of 3.30% from the previous year-end[4] - The company's total assets decreased to CNY 1,771,711,225.11 in 2025 from CNY 1,832,158,296.89 in 2024, a reduction of 3.3%[17] Shareholder Information - The top shareholder, Ningbo Free Trade Zone Yingweili Enterprise Management, holds 26.93% of shares[10] - The company maintained a basic and diluted earnings per share of CNY 0.10 for the first three quarters of 2025, down from CNY 0.28 in the same period of 2024[21] Operational Strategy - The company aims to enhance its product pipeline through a dual strategy of import substitution and clinical interaction[12] - The company holds a leading position with its proprietary LICA® technology platform, emphasizing cost-effective clinical products[12] - The company has a robust strategy to address unmet clinical needs and high-burden disease areas[12] Inventory and Costs - The company has maintained a stable inventory level, with inventory reported at CNY 113.82 million[15] - Total operating costs for the first three quarters of 2025 were CNY 223,690,330.27, down from CNY 234,109,060.40 in the previous year, reflecting a reduction of 4.0%[19] Liabilities and Tax - Total liabilities decreased to CNY 363,165,455.02 in 2025 from CNY 415,851,159.52 in 2024, a decline of 12.6%[17] - The company reported cash outflows for tax payments of $31.77 million in 2025, a decrease from $60.59 million in 2024, representing a reduction of 47.5%[24]